Clinical trial
Infliximab for the Treatment of Early Rheumatoid Arthritis
NCT00006292 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00006292 |
|---|---|
| Title | Infliximab for the Treatment of Early Rheumatoid Arthritis |
| Official title | Randomized Double Blind Active Treatment Controlled Trial of the Anti-TNF-Alpha Antibody Infliximab in Patients With Erosive Rheumatoid Arthritis |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 60 |
| Start date | Sep 1, 2000 |
| Completion | Sep 1, 2005 |
| First posted | Sep 25, 2000 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: